facebook
twitter
rss
account
search
search
 

FDA approves $1000 pill for Hepatitis C treatment

The drug is expected to shorten treatment of the disease and be less severe for patients but comes with a hefty price tag, and is expected to strain healthcare costs for these patients.
Posted By Ananth Baliga   |   Dec. 9, 2013 at 11:36 AM  |  Updated Dec. 9, 2013 at 12:40 PM   |   Comments

http://cdnph.upi.com/sv/em/upi_com/UPI-4691386607004/2013/1/35ef48ca1917fa8320d3818050b9cf0f/FDA-approves-1000-pill-for-Hepatitis-C-treatment.jpg
Dec. 9 (UPI) -- The Food and Drug Administration has approved Sovaldi, a new drug touted to effectively treat hepatitis C, but it comes with a steep price tag: $28,000 for four weeks or $1,000 per daily pill.

Sovaldi, manufactured by Gilead Sciences, has been shown in trials to safely and efficiently treat the disease without the need to additionally administer interferon. This makes it the second drug approved by the agency in the last two weeks for hepatitis treatment, the other being Olysio.

Hepatitis C is a viral disease that causes inflammation of the liver, which can lead to diminished liver function and liver failure. According to the Centers for Disease Control and Prevention 3.2 million persons in the United States have chronic Hepatitis C virus infection.

Until recently the most used treatment for the disease was 24 to 48 weeks of weekly injections of interferon alpha combined with daily tables of ribavirin. Neither of the drugs were created to fight hepatitis C.

In trials, Sovaldi was found to be effective across multiple types of the hepatitis C virus, even in those patients who could not tolerate interferon or interferon-based treatments.

The drug is only the third drug with "breakthrough therapy designation" to be approved by the FDA. Drugs which demonstrate a substantial improvement over available therapies for patients with serious or life-threatening diseases during initial clinical trials are given a breakthrough therapy designation.

But while there is interest in the drug's benefits, there is concern about the cost associated with the treatment.

“This is unbearable to the health care system and it is completely unjustified,” said Michael Weinstein, president of the AIDS Healthcare Foundation, which runs treatment clinics in the United States and abroad and has previously clashed with Gilead on the price of its drugs for H.I.V.


[FDA]
[CDC]
[The New York Times]

Follow @antbaliga and @UPI on Twitter.
Contact the Author
© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Featured UPI Collection
trending
Notable deaths of 2014 [PHOTOS]

Notable deaths of 2014 [PHOTOS]

Most Popular
1
Why the fake braces trend may be dangerous for users Why the fake braces trend may be dangerous for users
2
Jared Leto 'stopped eating' for his 'Dallas Buyer's Club' role Jared Leto 'stopped eating' for his 'Dallas Buyer's Club' role
3
Gisele Bundchen, Tom Brady drop $14M on Manhattan home Gisele Bundchen, Tom Brady drop $14M on Manhattan home
4
Kelly LeBrock arrested for DUI Kelly LeBrock arrested for DUI
5
Brandi Brandt faces drug charges in Australia Brandi Brandt faces drug charges in Australia
Trending News
Video
x
Feedback